# Chengdu Kanghong Biotech Co., Ltd. trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chengdu Kanghong Biotech Co., Ltd.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/chengdu-kanghong-biotech-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 7, 2026 | NCT07514975 | First-In-Human Study of KHN922 for Injection | Chengdu Kanghong Biotech Co., Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors Cancer | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514975) |
| March 20, 2025 | NCT06885645 | First-In-Human Study in Participants With Advanced Solid Tumors | Chengdu Kanghong Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885645) |
| August 4, 2021 | NCT04990271 | A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the... | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 | Unknown | Retinoblastoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04990271) |
| August 2, 2021 | NCT04985448 | Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity... | Chengdu Kanghong Biotech Co., Ltd. | Observational | Unknown | Retinopathy of Prematurity | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04985448) |
| September 18, 2020 | NCT04555304 | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 | Unknown | Gastric Cancer, Gastroesophageal Cancer | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04555304) |
| January 2, 2020 | NCT04215393 | An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization | Chengdu Kanghong Biotech Co., Ltd. | Phase 1 | Unknown | Corneal Neovascularization | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04215393) |
| August 15, 2018 | NCT03630952 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Terminated | Neovascular Age-related Macular Degeneration | 1,157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03630952) |
| July 5, 2018 | NCT03577899 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Terminated | Neovascular Age-related Macular Degeneration | 1,157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03577899) |
| August 9, 2017 | NCT03244657 | Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy | Chengdu Kanghong Biotech Co., Ltd. | Phase 4 | Unknown | Polypoid Choroidal Vasculopathy (PCV) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03244657) |
| July 21, 2017 | NCT03223714 | Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Completed | Macular Edema, Central Retinal Vein Occlusion | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03223714) |
| May 19, 2017 | NCT03159884 | The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) | Chengdu Kanghong Biotech Co., Ltd. | Phase 4 | Unknown | Polypoidal Choroidal Vasculopathy (PCV) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03159884) |
| April 11, 2017 | NCT03108352 | Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Completed | Branch Retinal Vein Occlusion, Macular Edema | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03108352) |
| February 16, 2017 | NCT03054818 | Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE） | Chengdu Kanghong Biotech Co., Ltd. | Observational | Unknown | Wet Age-related Macular Degeneration (wAMD) | 4,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03054818) |
| July 18, 2014 | NCT02194634 | Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Unknown | Diabetic Macular Edema | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02194634) |
| March 28, 2014 | NCT02098720 | An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular... | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 | Unknown | Very Low Vision Secondary to Wet Age-related Macular Degeneration | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02098720) |
| March 12, 2013 | NCT01809236 | Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 | Unknown | Retinal Vein Occlusion | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01809236) |
| March 12, 2013 | NCT01809223 | A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Unknown | Choroid Neovascularization Secondary to Degenerative Myopia | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01809223) |
| September 20, 2011 | NCT01436864 | A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 | Completed | Neovascular Age-related Macular Degeneration | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01436864) |
| March 29, 2011 | NCT01324869 | Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME) | Chengdu Kanghong Biotech Co., Ltd. | Phase 1/2 | Completed | Diabetic Macular Edema | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01324869) |
| November 16, 2010 | NCT01242254 | A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD | Chengdu Kanghong Biotech Co., Ltd. | Phase 1/2 | Completed | Neovascular Age-related Macular Degeneration | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01242254) |
| July 7, 2010 | NCT01157715 | A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 | Completed | Neovascular Age-related Macular Degeneration | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01157715) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 3 | 7 |
| Phase 4 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 11 |
| Completed | 6 |
| Not yet recruiting | 2 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Macular Degeneration | 3 |
| Choroidal Neovascularization | 3 |
| Retinal Vein Occlusion | 3 |
| Macular Edema | 2 |
| Polypoidal Choroidal Vasculopathy | 1 |
| Corneal Neovascularization | 1 |
| Retinopathy of Prematurity | 1 |
| Retinoblastoma | 1 |
| Stomach Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Commercial refrigeration companies in the United States](https://specstream.ai/data/businesses/commercial-refrigeration-companies/united-states)
- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
